Mauricio Garcia-Saenz-De-Sicilia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mauricio Garcia-Saenz-De-Sicilia has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Andres Duarte-Rojo
Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern Medicine, Feinberg School of Medicine, Chicago, Illinois, USA
3 shared publications - Emmanouil Giorgakis
Division of Abdominal Transplantation, Department of Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
2 shared publications Mohammad Al-Shoha
Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, 4301 W. Markham Slot #567, Little Rock, AR, 70205, United States
2 shared publicationsMohit Girotra
Department of Internal Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA
2 shared publicationsAlan Langnas
University of Nebraska Medical Center
1 shared publication- Amit Kumar Mathur
Division of Transplant Surgery, Department of Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Porto Sinusoidal Vascular Disorder Manifesting as Diffuse Arterio-Portal Fistulae and Portal Hypertension After Donation-After-Circulatory-Death Liver Transplantation
Ischemic cholangiopathy (ICP) is a rare complication of orthotopic liver transplantation (LT), with an increased incidence in donation-after-circulatory-death (DCD) recipients, particularly without machine perfusion. As DCD utilization increases, challenges arise. We report a rare case of DCD-LT resulting in ICP, complicated by diffuse intrahepatic arterio-portal fistulae (APF) leading to portal hypertension and refractory ascites without any other cause. The candidate was relisted for LT, and the explant revealed diffuse intrahepatic APF and porto-sinusoidal vascular disorder (PSVD) without cirrhosis. To the best of our knowledge, no similar reports exist of LT recipients developing PSVD or diffuse APF, and their concurrence with ICP after DCD-LT raises concern for an association. This case report highlights the importance of considering diffuse APF and PSVD in LT recipients with ICP who develop features of portal hypertension without a clear cirrhotic etiology.
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Open AccessPorto Sinusoidal Vascular Disorder Manifesting as Diffuse Arterio-Portal Fistulae and Portal Hypertension After Donation-After-Circulatory-Death Liver Transplantation
Ischemic cholangiopathy (ICP) is a rare complication of orthotopic liver transplantation (LT), with an increased incidence in donation-after-circulatory-death (DCD) recipients, particularly without machine perfusion. As DCD utilization increases, challenges arise. We report a rare case of DCD-LT resulting in ICP, complicated by diffuse intrahepatic arterio-portal fistulae (APF) leading to portal hypertension and refractory ascites without any other cause. The candidate was relisted for LT, and the explant revealed diffuse intrahepatic APF and porto-sinusoidal vascular disorder (PSVD) without cirrhosis. To the best of our knowledge, no similar reports exist of LT recipients developing PSVD or diffuse APF, and their concurrence with ICP after DCD-LT raises concern for an association. This case report highlights the importance of considering diffuse APF and PSVD in LT recipients with ICP who develop features of portal hypertension without a clear cirrhotic etiology.
- Open Access
- 30 December 2024
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 2
Metastatic Jejunal Adenocarcinoma in the Hepatobiliary Limb Post-Liver Transplant: Diagnostic Challenges in a Patient with Roux-en-Y Gastric Bypass
Background: The rise in bariatric surgeries, particularly Roux-en-Y gastric bypass (RYGB), has added complexity to diagnostic evaluations in post-transplant patients. Case Presentation: We present a rare case of metastatic jejunal adenocarcinoma in the biliopancreatic limb of a patient with a history of RYGB, diagnosed three months after simultaneous liver–kidney transplantation. Despite multiple advanced imaging modalities, the primary malignancy eluded detection during pre-transplant evaluation. The patient developed progressive anemia and persistent liver enzyme elevation, which led to a comprehensive diagnostic workup. After failed initial endoscopic and radiological attempts, a multifaceted approach combining PET-CT, targeted open liver biopsy, and repeat endoscopy via a G-tube site enabled the discovery of a 5 cm partially obstructing jejunal mass. Histopathological analysis confirmed moderately differentiated adenocarcinoma. Conclusions: This case underscores the challenges in diagnosing gastrointestinal malignancies in patients with altered anatomy, particularly following RYGB. It highlights the need for modified cancer screening protocols before organ transplantation, especially for those with complex post-surgical gastrointestinal anatomy, to prevent the development of metastatic disease post-transplant. Further research is warranted to refine screening strategies and improve early malignancy detection in this high-risk population.
- 30 December 2024
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 2
Open AccessMetastatic Jejunal Adenocarcinoma in the Hepatobiliary Limb Post-Liver Transplant: Diagnostic Challenges in a Patient with Roux-en-Y Gastric Bypass
Background: The rise in bariatric surgeries, particularly Roux-en-Y gastric bypass (RYGB), has added complexity to diagnostic evaluations in post-transplant patients. Case Presentation: We present a rare case of metastatic jejunal adenocarcinoma in the biliopancreatic limb of a patient with a history of RYGB, diagnosed three months after simultaneous liver–kidney transplantation. Despite multiple advanced imaging modalities, the primary malignancy eluded detection during pre-transplant evaluation. The patient developed progressive anemia and persistent liver enzyme elevation, which led to a comprehensive diagnostic workup. After failed initial endoscopic and radiological attempts, a multifaceted approach combining PET-CT, targeted open liver biopsy, and repeat endoscopy via a G-tube site enabled the discovery of a 5 cm partially obstructing jejunal mass. Histopathological analysis confirmed moderately differentiated adenocarcinoma. Conclusions: This case underscores the challenges in diagnosing gastrointestinal malignancies in patients with altered anatomy, particularly following RYGB. It highlights the need for modified cancer screening protocols before organ transplantation, especially for those with complex post-surgical gastrointestinal anatomy, to prevent the development of metastatic disease post-transplant. Further research is warranted to refine screening strategies and improve early malignancy detection in this high-risk population.
- 24 September 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 571-583
Prospective evaluation of cystatin C in the assessment of kidney dysfunction and survival in liver transplant candidates
Kidney dysfunction is associated with decreased survival in liver transplant (LT) candidates, yet serum creatinine (sCr) is a poor surrogate for glomerular filtration rate (GFR) in this population. Serum cystatin C (CysC) may provide a more accurate assessment of kidney function and predict outcomes. We performed a multicenter prospective cohort study of consecutive candidates for LT. CysC was obtained at LT evaluation (n = 244), and a subset underwent simultaneous I125-iothalamate clearance for measured GFR (mGFR) assessment (n = 137). Patients were followed to assess the need for pre-LT renal replacement therapy, simultaneous liver and kidney transplant, and survival. Estimated GFR (eGFR) based on MDRD-4, GRAIL, Royal Free Hospital Cirrhosis GFR, and the CKD-EPI equations was assessed for bias, precision, and accuracy in reference to mGFR. Receiver operator characteristic (AUROC) and competing risk survival analyses were performed. CysC more accurately discriminated mGFR than sCr at thresholds of ≤60 and ≤30 mL/min/1.73 m2 with AUROC 0.92 (p = 0.005) and 0.96 (p=0.01), respectively. All eGFR equations overestimated GFR, especially among females (p < 0.05). The GRAIL equation demonstrated the least bias, while CKD-EPI-cystatin C was associated with the greatest precision and lowest frequency of GFR overestimation. Among 165 recipients of LT, CysC discriminated pre-LT renal replacement therapy and the need for simultaneous liver and kidney transplant with AUROC of 0.70 and 0.85, respectively. Cumulative incidence of death, accounting for LT as a competing event, increased with CysC (p = 0.002) but was not observed with sCr overall or among subgroups (p = NS). CysC more accurately predicts thresholds of mGFR than sCr in candidates for LT. Elevated CysC discriminates pre-LT renal replacement therapy and simultaneous liver and kidney transplant and is strongly associated with survival in contrast with sCr. CysC is a promising tool to improve prognostication among candidates for LT.
- 24 September 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 571-583
Prospective evaluation of cystatin C in the assessment of kidney dysfunction and survival in liver transplant candidates
Kidney dysfunction is associated with decreased survival in liver transplant (LT) candidates, yet serum creatinine (sCr) is a poor surrogate for glomerular filtration rate (GFR) in this population. Serum cystatin C (CysC) may provide a more accurate assessment of kidney function and predict outcomes. We performed a multicenter prospective cohort study of consecutive candidates for LT. CysC was obtained at LT evaluation (n = 244), and a subset underwent simultaneous I125-iothalamate clearance for measured GFR (mGFR) assessment (n = 137). Patients were followed to assess the need for pre-LT renal replacement therapy, simultaneous liver and kidney transplant, and survival. Estimated GFR (eGFR) based on MDRD-4, GRAIL, Royal Free Hospital Cirrhosis GFR, and the CKD-EPI equations was assessed for bias, precision, and accuracy in reference to mGFR. Receiver operator characteristic (AUROC) and competing risk survival analyses were performed. CysC more accurately discriminated mGFR than sCr at thresholds of ≤60 and ≤30 mL/min/1.73 m2 with AUROC 0.92 (p = 0.005) and 0.96 (p=0.01), respectively. All eGFR equations overestimated GFR, especially among females (p < 0.05). The GRAIL equation demonstrated the least bias, while CKD-EPI-cystatin C was associated with the greatest precision and lowest frequency of GFR overestimation. Among 165 recipients of LT, CysC discriminated pre-LT renal replacement therapy and the need for simultaneous liver and kidney transplant with AUROC of 0.70 and 0.85, respectively. Cumulative incidence of death, accounting for LT as a competing event, increased with CysC (p = 0.002) but was not observed with sCr overall or among subgroups (p = NS). CysC more accurately predicts thresholds of mGFR than sCr in candidates for LT. Elevated CysC discriminates pre-LT renal replacement therapy and simultaneous liver and kidney transplant and is strongly associated with survival in contrast with sCr. CysC is a promising tool to improve prognostication among candidates for LT.
- Open Access
- 8 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7537-7551
Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future
Hepatocellular carcinoma (HCC) is one of the leading indications for liver transplantation and has been the treatment of choice due to the oncologic benefit for patients with advanced chronic liver disease (AdvCLD) and small tumors for the last 25 years. For HCC patients undergoing liver transplantation, alpha fetoprotein (AFP) has increasingly been applied as an independent predictor for overall survival, disease free recurrence, and waitlist drop out. In addition to static AFP, newer studies evaluating the AFP dynamic response to downstaging therapy show enhanced prognostication compared to static AFP alone. While AFP has been utilized to select HCC patients for transplant, despite years of allocation policy changes, the US allocation system continues to take a uniform approach to HCC patients, without discriminating between those with favorable or unfavorable tumor biology. We aim to review the history of liver allocation for HCC in the US, the utility of AFP in liver transplantation, the implications of weaving AFP as a biomarker into policy. Based on this review, we encourage the US transplant community to revisit its HCC organ allocation model, to incorporate more precise oncologic principles for patient selection, and to adopt AFP dynamics to better stratify waitlist dropout risk.
- 8 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7537-7551
Open AccessHepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future
Hepatocellular carcinoma (HCC) is one of the leading indications for liver transplantation and has been the treatment of choice due to the oncologic benefit for patients with advanced chronic liver disease (AdvCLD) and small tumors for the last 25 years. For HCC patients undergoing liver transplantation, alpha fetoprotein (AFP) has increasingly been applied as an independent predictor for overall survival, disease free recurrence, and waitlist drop out. In addition to static AFP, newer studies evaluating the AFP dynamic response to downstaging therapy show enhanced prognostication compared to static AFP alone. While AFP has been utilized to select HCC patients for transplant, despite years of allocation policy changes, the US allocation system continues to take a uniform approach to HCC patients, without discriminating between those with favorable or unfavorable tumor biology. We aim to review the history of liver allocation for HCC in the US, the utility of AFP in liver transplantation, the implications of weaving AFP as a biomarker into policy. Based on this review, we encourage the US transplant community to revisit its HCC organ allocation model, to incorporate more precise oncologic principles for patient selection, and to adopt AFP dynamics to better stratify waitlist dropout risk.
- 1 March 2022
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 12 (2) , 319-328
Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation
- 1 March 2022
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 12 (2) , 319-328
Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation
- 1 April 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (4) , 491-494
Hepatic Steatosis and its Effects on Fibrosis in Patients With Chronic Hepatitis B Virus Infection
- 1 April 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (4) , 491-494
Hepatic Steatosis and its Effects on Fibrosis in Patients With Chronic Hepatitis B Virus Infection
- 5 February 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2132-2139
Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm
Ipilimumab is a cytotoxic T-lymphocyte-associated antigen-4-blocking monoclonal antibody, which has shown a significant survival benefit in metastatic melanoma patients. Despite being a promising therapy for a disease with an otherwise rather dismal prognosis, it is associated with several immune-related adverse effects (IRAE) mainly targeted toward the digestive tract, skin, liver, and hypothalamic-pituitary axis. Ipilimumab-induced gastrointestinal toxicity (IGT) include diarrhea (~44 %), colitis (~18 %), bowel perforation (<1 %), and pancreatitis (<1.5 %). Early recognition of IRAE and treatment initiation are critical to decrease the risk of further complications. Management included steroids as initial therapy, followed by infliximab (anti-tumor necrosis factor alpha antibody) and/or surgical option for complications like bowel perforation. We present a series of three patients with metastatic melanoma, who received treatment with ipilimumab, and presented with varying gastrointestinal clinical manifestations and complications. Through this case series, our attempt is to make practicing gastroenterologists cognizant about the wide spectrum of gastrointestinal toxicity of this rather new clinical entity, as well as to discuss management algorithm for IGT.
- 5 February 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2132-2139
Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm
Ipilimumab is a cytotoxic T-lymphocyte-associated antigen-4-blocking monoclonal antibody, which has shown a significant survival benefit in metastatic melanoma patients. Despite being a promising therapy for a disease with an otherwise rather dismal prognosis, it is associated with several immune-related adverse effects (IRAE) mainly targeted toward the digestive tract, skin, liver, and hypothalamic-pituitary axis. Ipilimumab-induced gastrointestinal toxicity (IGT) include diarrhea (~44 %), colitis (~18 %), bowel perforation (<1 %), and pancreatitis (<1.5 %). Early recognition of IRAE and treatment initiation are critical to decrease the risk of further complications. Management included steroids as initial therapy, followed by infliximab (anti-tumor necrosis factor alpha antibody) and/or surgical option for complications like bowel perforation. We present a series of three patients with metastatic melanoma, who received treatment with ipilimumab, and presented with varying gastrointestinal clinical manifestations and complications. Through this case series, our attempt is to make practicing gastroenterologists cognizant about the wide spectrum of gastrointestinal toxicity of this rather new clinical entity, as well as to discuss management algorithm for IGT.
- Open Access
- 1 January 2015
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 2 (1) , 227-229
Magnesium Toxicity-Induced Ileus in a Postpartum Patient Treated for Preeclampsia With Magnesium Sulphate
Hypermagnesemia is a rare and under-recognized cause of paralytic ileus. We report a case of a 21-year-old primigravida who was managed aggressively for preeclampsia and presented with postpartum paralytic ileus. Detailed history was employed to consider hypermagnesemia-induced ileus as the working diagnosis, and the patient improved with correction of the electrolyte imbalance. Hypermagnesemia-induced lethargy, decreased reflexes, muscle weakness, flaccid paralysis, respiratory muscle paralysis, and cardiac arrest are well-described; however, intestinal smooth muscle dysfunction leading to paralytic ileus has never been reported in the setting of magnesium use for peripartum preeclampsia management.
- 1 January 2015
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 2 (1) , 227-229
Open AccessMagnesium Toxicity-Induced Ileus in a Postpartum Patient Treated for Preeclampsia With Magnesium Sulphate
Hypermagnesemia is a rare and under-recognized cause of paralytic ileus. We report a case of a 21-year-old primigravida who was managed aggressively for preeclampsia and presented with postpartum paralytic ileus. Detailed history was employed to consider hypermagnesemia-induced ileus as the working diagnosis, and the patient improved with correction of the electrolyte imbalance. Hypermagnesemia-induced lethargy, decreased reflexes, muscle weakness, flaccid paralysis, respiratory muscle paralysis, and cardiac arrest are well-described; however, intestinal smooth muscle dysfunction leading to paralytic ileus has never been reported in the setting of magnesium use for peripartum preeclampsia management.
- 28 May 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (11) , 2804-2812
Impact of Anti-Thymocyte Globulin During Immunosuppression Induction in Patients with Hepatitis C After Liver Transplantation
Induction immunosuppression with anti-thymocyte globulin (ATG) provides potential benefits after liver transplantation (LT). However, its use in patients with LT and hepatitis C (HCV) is controversial.
- 28 May 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (11) , 2804-2812
Impact of Anti-Thymocyte Globulin During Immunosuppression Induction in Patients with Hepatitis C After Liver Transplantation
Induction immunosuppression with anti-thymocyte globulin (ATG) provides potential benefits after liver transplantation (LT). However, its use in patients with LT and hepatitis C (HCV) is controversial.
- 1 September 2012
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 5 (5) , 587-593
The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice
Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxicity and metabolic abnormalities, to name a few. Over the last decade, tremendous interest has also focused on the impact of these medications on the replication of hepatitis C virus (HCV), with cyclosporine in particular having a negative effect on viral replication in vitro. Although small retrospective studies suggested that there may be a beneficial effect with cyclosporine on the progression of recurrent HCV and response to interferon, these findings have not been validated in several well-designed randomized controlled trial studies. The authors will review the pharmacology and pharmacokinetics of these well-known drugs and discuss the impact of these medications on the natural history of HCV recurrence after liver transplantation.
- 1 September 2012
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 5 (5) , 587-593
The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice
Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxicity and metabolic abnormalities, to name a few. Over the last decade, tremendous interest has also focused on the impact of these medications on the replication of hepatitis C virus (HCV), with cyclosporine in particular having a negative effect on viral replication in vitro. Although small retrospective studies suggested that there may be a beneficial effect with cyclosporine on the progression of recurrent HCV and response to interferon, these findings have not been validated in several well-designed randomized controlled trial studies. The authors will review the pharmacology and pharmacokinetics of these well-known drugs and discuss the impact of these medications on the natural history of HCV recurrence after liver transplantation.